Anzeige
Meldung des Tages: HydroGraph stieg von 0,20 auf 11,30 – ist diese Graphen-Aktie bei 0,37 als Nächste dran?!

BioLineRX Aktie (ADR) News

Aktie
WKN:  A41038 ISIN:  US09071M3043 US-Symbol:  BLRX Branche:  Biotechnologie Land:  Israel
2,24 $
+0,00 $
0,00%
1,9097 € 22.04.26
Depot/Watchlist
Marktkapitalisierung *
4,96 Mio. €
Streubesitz
94,93%
KGV
-3,67
Index-Zuordnung
-

BioLineRX Aktie (ADR) News

26.03.26 - PR Newswire
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) PR Newswire
23.03.26 - PR Newswire
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
BioLineRx Reports 2025 Financial Results and Provides Corporate Update PR Newswire
16.03.26 - PR Newswire
BioLineRx to Report 2025 Annual Results on March 23, 2026
BioLineRx to Report 2025 Annual Results on March 23, 2026 PR Newswire
24.11.25 - PR Newswire
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
18.11.25 - PR Newswire
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 PR Newswire
17.11.25 - PR Newswire
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types PR Newswire
29.09.25 - PR Newswire
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-​in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other ...
14.08.25 - PR Newswire
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
07.08.25 - PR Newswire
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 PR Newswire
30.05.25 - PR Newswire
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-​Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting ...
27.05.25 - PR Newswire
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
20.05.25 - PR Newswire
BioLineRx to Report First Quarter 2025 Results on May 27, 2025
BioLineRx to Report First Quarter 2025 Results on May 27, 2025 PR Newswire

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »